linjc16/ctgov huggingface dataset:
Impact of External Nasal Dilator on the Rhinogram

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to present new data for a better understanding of the anatomic correlation of these two notches. This study included 32 nasal cavities (16 individuals) with external nasal dilator strip (Breath Right®) and after decongestion (0.05% oxymetazoline chloride applied as an aerosol spray);

Detailed Description
-----------------
Acoustic rhinometry is more accurate in the anterior portion of the nasal cavities, from the nostril to the nasal valve (NV), the most important site of nasal obstruction. Literature presents different opinions regarding the anatomical correlation of the two notches at the beginning of the rhinogram curve in normal adult Caucasian individuals. This prospective study included 32 nasal cavities under the following conditions: 1st - basal condition; 2nd - with external nasal dilator strip (ENDS) (Breath Right®); 3rd - after decongestion (0.05% oxymetazoline chloride applied as an aerosol spray); 4th - after decongestion with ENDS.

Official Title
-----------------
Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram

Conditions
-----------------
Nasal Obstruction

Intervention / Treatment
-----------------
* Drug: External Nasal Dilator Strip; 0.05% oxymetazoline chloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult, Caucasian Exclusion Criteria: Allergies, sinusitis, nasal polyps, external nasal deformities congenital or acquired, obstructive nasal deviation and regular use of any drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| External nasal dilator, decongestion<br> | Drug: External Nasal Dilator Strip; 0.05% oxymetazoline chloride<br>* External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.<br>* Other names: Breath Right®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
external nasal dilator strip, nasal valve, acoustic rhinometry
ARTEMIS Synovial Markers in Arthritis Childhood

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.

Official Title
-----------------
ARTEMIS Synovial Markers in Arthritis Childhood

Conditions
-----------------
Septic Arthritis, Juvenile Idiopathic Arthritis

Intervention / Treatment
-----------------
* Procedure: Articular punction, salivary samples, blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Septic arthritis with bacteriological identification Juvenile idiopathic arthritis beyond the ILAR definition Having acute arthritis requiring an articular draining Child benefiting from a national insurance scheme Collection of the consent of the parents or the legal representative Exclusion Criteria: Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)> 1,5 Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining. Treatment by antibiotic begun more than 24 hours before the draining.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Septic arthritis<br>with bacteriological identification | Procedure: Articular punction, salivary samples, blood sample<br> <br> * Other names: Monocyte;|
| Other: Juvenile idiopathic arthritis<br>beyond the ILAR (International League of Associations for Rheumatology) definition | Procedure: Articular punction, salivary samples, blood sample<br> <br> * Other names: Monocyte;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis. | Identify blood sampling biomarkers of Arthritis childhood | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arthritis, septic, Juvenile idiopathic arthritis, diagnosis, proteomic, cytokine, monocytes
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obsessive-Compulsive Disorder

Study Overview
=================
Brief Summary
-----------------
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed Description
-----------------
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to infection with Obsessive-Compulsive Disorder.

Official Title
-----------------
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obsessive-Compulsive Disorder (OCD)

Conditions
-----------------
Obsessive-Compulsive Disorder

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent Male or female of all ages OCI greater than or equal to 21 Exclusion Criteria: Refusal to sign informed consent form History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. Postoperative stoma, ostomy, or ileoanal pouch Participation in any experimental drug protocol within the past 12 weeks Treatment with total parenteral nutrition
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obsessive-Compulsive Disorder<br>Patients with obsessive-compulsive disorder | Other: No Intervention<br>* There is no intervention for this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing | Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with Obsessive-Compulsive Disorder | Three years |
D-serine in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Official Title
-----------------
The Effects of Add-On D-serine Pharmacotherapy in Chronic Treatment Resistant Schizophrenia Patients

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Dietary Supplement: D-serine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items Exclusion Criteria: clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo<br>starch | Dietary Supplement: D-serine<br>* dosage<br>* Other names: placebo;|
| High Dose<br>3.5 g/d D-serine adjuvant treatment | Dietary Supplement: D-serine<br>* dosage<br>* Other names: placebo;|
| Low Dose<br>2.1 g/d D-serine adjuvant treatment | Dietary Supplement: D-serine<br>* dosage<br>* Other names: placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS Total Score |  | 6 weeks |
Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

Study Overview
=================
Brief Summary
-----------------
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Conditions
-----------------
TACE, Hepatocellular Carcinoma, Notch1, Rg3

Intervention / Treatment
-----------------
* Procedure: TACE
* Drug: Rg3
* Other: TACE + Rg3
* Procedure: protective therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed hepatocellular carcinoma. High expression of Notch1 in tumor tissues. Exclusion Criteria: no pathological evidence of HCC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TACE<br>iodized oil (5ml) + Pirarubicin (20mg) | Procedure: TACE<br>* iodized oil (5ml) + Pirarubicin (20mg)<br>* Other names: Transcatheter Arterial Chemoembolization;|
| Experimental: Rg3<br>20mg, BID, maintained though Month 12 | Drug: Rg3<br>* 20mg, BID, maintained though Month 12.<br>|
| Experimental: TACE + Rg3<br>the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE. | Other: TACE + Rg3<br> <br> |
| Experimental: Control<br>standard liver protective therapy | Procedure: protective therapy<br>* standard liver protective therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 3 years | 
| Time to progression |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carcinoma, Hepatocellular, Notch1
FR in Stored Plasma

Study Overview
=================
Brief Summary
-----------------
The folate receptor (FR) is a cell over expressed on the surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues, the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to target cancers which overexpress the FR while reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. Once such drug BGC945 is currently being tested in preclinical study at the Institute of Cancer Research

Detailed Description
-----------------
FR may be released from the cancer cells in the blood. We have developed a method in the laboratory which has been able to measure the FR obtained from cancer cells in culture which has been added into blood. We would like to study if this method is able to measure the FR in stored plasma samples obtained from patients with ovarian cancer, so that it may be developed as a method for selecting patients for FR-target treatments such as BGC 945.

Official Title
-----------------
Measurement of the Folate Receptor in Stored Plasma From Patients With Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ovarian cancer who have given informed consent to have blood collected for the plasma bank in the 'Pharmacogenetics and proteomics studies in patients receiving novel anticaner agents' study. Exclusion Criteria: Patients who have withdrawn consent form their blood stored within the 'Pharmacogenetics and proteomics studies in patients receiving novel anticancer agents' study to be used for research.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure the levels of soluble folate receptor in stored plasma obtained from patients with ovarian cancer |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ovarian cancer, folate receptor, plasma
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Study Overview
=================
Brief Summary
-----------------
Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

Official Title
-----------------
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Sulforaphane
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more. BMI increase of 10% or more since initiation of HIV treatment over a year period. BMI equal to or greater than 30. 18-85 years of age. Exclusion Criteria: Cancer Pregnancy or breastfeeding Intolerance to cruciferous vegetables Intolerance to sulforaphane Gluten Intolerance Creatinine > 1.3 mg/dL GFR < 60 AST or ALT > 1.5 times upper limit of normal. White cell count < 2000 cells per ml. Hemoglobin < 10.5 g/dL. Platelet count < 140,000 per ml.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sulforaphane Group<br> | Drug: Sulforaphane<br>* 40 mg of Sulforaphane powder once daily.<br>|
| Placebo Comparator: Placebo Group<br> | Other: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lipids | Triglycerides, Cholesterol | 4 months | 
| Inflammatory Markers | CRP | 4 months |
Desk Cycling Work Performance Evaluation

Study Overview
=================
Brief Summary
-----------------
This lab study is evaluating the feasibility of accomplishing productive office work while simultaneously pedaling a compact desk-based cycling device.

Official Title
-----------------
Desk-Compatible Elliptical Device: Feasibility Evaluation

Conditions
-----------------
Obesity, Physical Activity, Overweight

Intervention / Treatment
-----------------
* Behavioral: Compact Cycling Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years Ability to type without looking at the keyboard Native English speaker Normal hearing Spend 6 or more hours per day sitting Less than 150 minutes of physical activity per week Exclusion Criteria: Positive response on the Physical Activity Readiness Questionnaire indicating that low intensity pedaling could present safety risks Pregnancy Body mass index less than 18 or greater than 35

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Seated<br>Participants completed work tasks while seated. | Behavioral: Compact Cycling Device<br>* Participants pedaled a compact cycling device while simultaneously working at a desk.<br>|
| Experimental: Low Intensity Pedaling<br>Participants completed work tasks while pedaling at a low intensity. | Behavioral: Compact Cycling Device<br>* Participants pedaled a compact cycling device while simultaneously working at a desk.<br>|
| Experimental: Low-Moderate Intensity Pedaling<br>Participants completed work tasks while pedaling at a low-moderate intensity. | Behavioral: Compact Cycling Device<br>* Participants pedaled a compact cycling device while simultaneously working at a desk.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Typing task | Participants completed a computerized typing task | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reading task | Participants read a brief passage and answered questions to assess reading comprehension. | 5 minutes | 
| Logic Reasoning and Phone Task | Participants completed logical reasoning questions while answering a simulated phone call. | 5 minutes |
A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects of oral oxybutynin and intradetrusor injections of botulinum toxin type A on urodynamic parameters and quality of life in patients with neurogenic detrusor overactivity following spinal cord injury.

Official Title
-----------------
A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

Conditions
-----------------
Spinal Cord Injury

Intervention / Treatment
-----------------
* Drug: Oxybutynin
* Drug: Botulinum toxin A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Spinal cord injury Detrusor overactivity Age over 18 years Spinal cord injury at least 12 months duration Undergoing regular clean intermittent catheterisation Exclusion Criteria: Pregnancy Desire to become pregnant during the study period Breastfeeding Blood coagulation disorder Neuromuscular transmission disorder Use of any intravesical pharmacologic agents Previous use of botulinum toxin A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Botulinum toxin A<br> | Drug: Oxybutynin<br>* 5 mg of immediate-release oxybutynin orally 3 times daily<br>Drug: Botulinum toxin A<br>* 300 U intradetrusor injection<br>|
| Active Comparator: oxybutynin<br> | Drug: Oxybutynin<br>* 5 mg of immediate-release oxybutynin orally 3 times daily<br>Drug: Botulinum toxin A<br>* 300 U intradetrusor injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary study outcome measure was the variation mean in the number of episodes of urinary incontinence per 24 hours, maximum cystometric capacity, maximum detrusor pressure and bladder compliance |  | Beginning and 24 weeks of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary outcome measure was quality of life as measured by the Qualiveen questionnaire |  | Beginning and 24 weeks of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurogenic bladder, Urodynamic, Quality of life